VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023.
Conference Call/Webcast Information:
| Date: | Wednesday, August 9, 2023 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-In: | (800) 715-9871 or (646) 307-1963 for international callers |
| Conference ID: | 7071952 |
A live audio webcast will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$40.45 |
| Daily Change: | -0.13 -0.32 |
| Daily Volume: | 317,598 |
| Market Cap: | US$3.050B |
May 09, 2024 May 07, 2024 April 16, 2024 April 10, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
